Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA222298 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Approximately half of women diagnosed with advanced triple negative breast cancer (TNBC) will develop brain metastases, of which the majority will have uncontrolled extracranial disease. While local therapies to treat brain metastases are standardly prescribed, survival remains less than 6 months. This phase II, multi-center trial evaluated efficacy of irinotecan and iniparib, anti-cancer agents with activity in TNBC and known to cross the blood brain barrier, among 34 patients with new or progressive TNBC brain metastases. While time to progression was short (2.1 months), 27% of patients experienced intracranial clinical benefit and therapy was well-tolerated. Correlative studies illustrate partial response was associated with germline BRCA mutation status and high tumor expression of proliferation genes and signatures. To our knowledge, this is the first study showing feasibility of enrolling patients with progressive TNBC brain metastases to a systemic therapy and lays the groundwork for future studies to treat this devastating disease.
2014-12-31 | GSE51280 | GEO
Project description:TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer
| PRJNA131093 | ENA
Project description:cmLumiOpto gene therapy in combination with chemotherapy to treat triple negative breast cancer.
| PRJNA1308851 | ENA
Project description:Seviteronel plus chemotherapy is a new targeted combination therapy to treat triple-negative breast cancer
| PRJNA764708 | ENA
Project description:The EWS::FLI1 transcription factor drives the growth of Ewing sarcoma (ES). Trabectedin above a threshold concentration reverses the activity of EWS::FLI1, which is potentiated in vivo by low dose irinotecan. This open label phase 1/2 trial of trabectedin with irinotecan enrolled 37 relapsed/refractory ES patients (SARC037; NCT04067115). The recommended phase 2 dose (RP2D) was trabectedin 1.0 mg/m2 over 1 hour (Day 1) and irinotecan 25 mg/m2 (Days 2 & 4) of 21-day cycle. Toxicities were manageable with >Grade 3 toxicities (>15%) of myelosuppression and ALT elevations at RP2D. The phase 2 objective response rate was 33% (39%, including RP2D phase 1 patients) and 6-month PFS was 48%. Transcriptional profiling demonstrated reversal of the EWS::FLI1 transcriptome in tumors from a subset of patients. Additional correlative objectives captured molecular profiling, ctDNA levels, and 18F-FLT PET avidity. The combination of trabectedin and irinotecan is active in ES and suppresses its driver, EWS::FLI1.
2026-03-02 | GSE322664 | GEO
Project description:The EWS::FLI1 transcription factor drives the growth of Ewing sarcoma (ES). Trabectedin above a threshold concentration reverses the activity of EWS::FLI1, which is potentiated in vivo by low dose irinotecan. This open label phase 1/2 trial of trabectedin with irinotecan enrolled 37 relapsed/refractory ES patients (SARC037; NCT04067115). The recommended phase 2 dose (RP2D) was trabectedin 1.0 mg/m2 over 1 hour (Day 1) and irinotecan 25 mg/m2 (Days 2 & 4) of 21-day cycle. Toxicities were manageable with >Grade 3 toxicities (>15%) of myelosuppression and ALT elevations at RP2D. The phase 2 objective response rate was 33% (39%, including RP2D phase 1 patients) and 6-month PFS was 48%. Transcriptional profiling demonstrated reversal of the EWS::FLI1 transcriptome in tumors from a subset of patients. Additional correlative objectives captured molecular profiling, ctDNA levels, and 18F-FLT PET avidity. The combination of trabectedin and irinotecan is active in ES and suppresses its driver, EWS::FLI1.
2026-03-02 | GSE322640 | GEO
Project description:Chemotherapy is the mainstay treatment stragety for triple negative breast cancer (TNBC). However resistance to chemotherapy is common, leading to disease progression and death. Strategies that improve chemotherapy efficacy has the potential to reduce TNBC mortality. In this research, we demonstrated that the pan-PI3K inhibitor copanlisib, which is already in clinic to treat hematologic malignancies, enhanced the cytotoxicity of eribulin, a common chemotherapy used to treat taxane-resistant TNBC, in a panel of TNBC patient-derived xenograft (PDX) models. The improved tumor growth inhibition was irrespective of PI3K pathway alteration and was corroborated by the enhanced apoptotic induction observed in PDX tumors post combination therapy compared to each drug alone. The combination therapy inhibited eribulin-induced PI3K pathway activation, providing an underlying mechanism of action for its enhanced anti-tumor effect. Based on these results, a Phase I/II trial of this combination in patients with metastatic TNBC was initiated and is ongoing.
2024-04-26 | GSE243865 | GEO
Project description:TBCRC 039: A phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
| PRJNA973715 | ENA
Project description:Advanced colorectal cancer (CRC) is an unresolved clinical problem. Epigenetic drugs belonging to the group of histone deacetylase inhibitors (HDACi) may combat CRC in rationally designed treatment schedules. Unfortunately, there is sparse evidence on molecular mechanisms and markers that determine cellular sensitivity to HDACi. Irinotecan is widely used to treat CRC and causes replication stress (RS) and DNA damage as topoisomerase-I inhibitor. We applied irinotecan and the class I HDACi entinostat (MS-275) to isogenic p53-positive and -negative CRC cells. Combinations of irinotecan and MS-275 evoke mitochondrial damage, caspase-mediated apoptosis, and RS-associated DNA damage synergistically and p53-dependently. Targeted mass spectrometry and immunoblot show that irinotecan induces phosphorylation, acetylation, and accumulation of p53 and its target genes. Addition of MS-275 augments the irinotecan-induced acetylation of C-terminal lysine residues of p53 but decreases its phosphorylation and p53 target gene induction. Furthermore, MS-275 increases the amount of acetylated p53 at mitochondria and dysregulates the expression of pro- and anti-apoptotic BCL2 proteins in irinotecan-treated cells. Regarding DNA repair, we see that MS-275 represses the homologous recombination (HR) filament protein RAD51, which limits DNA damage and pro-apoptotic effects of irinotecan. These data suggest that key class I HDAC-dependent functions of p53 in cells with RS are linked to mitochondrial damage and a breakdown of HR. Most importantly, combinations of irinotecan plus MS-275 also kill short-term primary CRC cell cultures and organoids from CRC patients but spare organoids of adjacent matched normal tissue. Thus, irinotecan/HDACi treatment is a promising new approach for the therapy of p53-proficient tumors with clinically tractable inhibitors.
2022-02-15 | PXD019999 | Pride
Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors
2018-07-01 | GSE98931 | GEO